{"id":"fec75","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"20-50%","effect":"Diarrhea"},{"rate":"30-60%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This regimen works by inhibiting DNA synthesis and function, causing cell death in rapidly dividing cancer cells. The combination of these three drugs targets different stages of the cell cycle, increasing the effectiveness of the treatment. However, this also increases the risk of side effects.","oneSentence":"FEC75 is a chemotherapy regimen that combines 5-fluorouracil, epirubicin, and cyclophosphamide to treat breast cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:53:47.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of node-positive breast cancer"},{"name":"Treatment of metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT04324346","phase":"NA","title":"Central Catheters Used for Chemotherapy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Swedish Red Cross University College","startDate":"2016-04-01","conditions":"Catheter Related Complications","enrollment":250},{"nctId":"NCT00513292","phase":"PHASE3","title":"Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07","conditions":"HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer","enrollment":280},{"nctId":"NCT00524303","phase":"PHASE2","title":"Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Neoplasms, Breast","enrollment":100},{"nctId":"NCT00756470","phase":"PHASE2","title":"Phase II Neoadjuvant in Inflammatory Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-10","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT00286819","phase":"PHASE2","title":"Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer","status":"COMPLETED","sponsor":"Central European Cooperative Oncology Group","startDate":"2005-04","conditions":"Breast Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FEC75","genericName":"FEC75","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FEC75 is a chemotherapy regimen that combines 5-fluorouracil, epirubicin, and cyclophosphamide to treat breast cancer. Used for Adjuvant treatment of node-positive breast cancer, Treatment of metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}